Caplin Point Laboratories Limited

NSEI:CAPLIPOINT Stock Report

Market Cap: ₹147.7b

Caplin Point Laboratories Valuation

Is CAPLIPOINT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAPLIPOINT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CAPLIPOINT (₹1942.8) is trading above our estimate of fair value (₹1260.43)

Significantly Below Fair Value: CAPLIPOINT is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAPLIPOINT?

Key metric: As CAPLIPOINT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CAPLIPOINT. This is calculated by dividing CAPLIPOINT's market cap by their current earnings.
What is CAPLIPOINT's PE Ratio?
PE Ratio29.9x
Earnings₹4.94b
Market Cap₹147.73b

Price to Earnings Ratio vs Peers

How does CAPLIPOINT's PE Ratio compare to its peers?

The above table shows the PE ratio for CAPLIPOINT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.2x
MARKSANS Marksans Pharma
40.4x22.3%₹140.1b
STAR Strides Pharma Science
78.1x45.6%₹138.3b
532482 Granules India
27.1x22.1%₹132.2b
GLS Glenmark Life Sciences
31.2x23.4%₹132.3b
CAPLIPOINT Caplin Point Laboratories
29.9x13.6%₹147.7b

Price-To-Earnings vs Peers: CAPLIPOINT is good value based on its Price-To-Earnings Ratio (29.9x) compared to the peer average (44.2x).

Price to Earnings Ratio vs Industry

How does CAPLIPOINT's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
CAPLIPOINT 29.9xIndustry Avg. 32.2xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CAPLIPOINT is good value based on its Price-To-Earnings Ratio (29.9x) compared to the Indian Pharmaceuticals industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is CAPLIPOINT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAPLIPOINT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.9x
Fair PE Ratio35.9x

Price-To-Earnings vs Fair Ratio: CAPLIPOINT is good value based on its Price-To-Earnings Ratio (29.9x) compared to the estimated Fair Price-To-Earnings Ratio (35.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAPLIPOINT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,942.80
₹2,396.67
+23.4%
3.9%₹2,510.00₹2,280.00n/a3
Nov ’25₹2,024.75
₹2,141.67
+5.8%
7.6%₹2,365.00₹1,980.00n/a3
Oct ’25₹2,078.20
₹1,976.00
-4.9%
4.4%₹2,080.00₹1,868.00n/a3
Sep ’25₹1,905.00
₹1,882.67
-1.2%
3.9%₹1,980.00₹1,800.00n/a3
Aug ’25₹1,583.85
₹1,568.67
-1.0%
4.2%₹1,660.00₹1,511.00n/a3
Jul ’25₹1,452.35
₹1,568.67
+8.0%
4.2%₹1,660.00₹1,511.00n/a3
Jun ’25₹1,290.30
₹1,579.33
+22.4%
3.6%₹1,660.00₹1,535.00n/a3
May ’25₹1,356.45
₹1,579.33
+16.4%
3.6%₹1,660.00₹1,535.00n/a3
Apr ’25₹1,371.75
₹1,579.33
+15.1%
3.6%₹1,660.00₹1,535.00n/a3
Mar ’25₹1,527.05
₹1,601.50
+4.9%
3.7%₹1,660.00₹1,543.00n/a2
Feb ’25₹1,400.35
₹1,471.50
+5.1%
4.9%₹1,543.00₹1,400.00n/a2
Jan ’25₹1,355.95
₹1,471.50
+8.5%
4.9%₹1,543.00₹1,400.00n/a2
Dec ’24₹1,294.45
₹1,281.00
-1.0%
21.5%₹1,543.00₹900.00n/a3
Nov ’24₹1,020.60
₹996.33
-2.4%
11.7%₹1,160.00₹900.00₹2,024.753
Oct ’24₹1,030.85
₹995.00
-3.5%
11.8%₹1,160.00₹900.00₹2,078.203
Sep ’24₹1,096.30
₹995.00
-9.2%
11.8%₹1,160.00₹900.00₹1,905.003
Aug ’24₹907.45
₹925.00
+1.9%
2.2%₹950.00₹900.00₹1,583.853
Jul ’24₹806.55
₹925.00
+14.7%
2.7%₹950.00₹900.00₹1,452.352
Jun ’24₹756.75
₹925.00
+22.2%
2.7%₹950.00₹900.00₹1,290.302
May ’24₹678.30
₹907.50
+33.8%
4.7%₹950.00₹865.00₹1,356.452
Apr ’24₹595.95
₹907.50
+52.3%
4.7%₹950.00₹865.00₹1,371.752
Mar ’24₹659.90
₹903.33
+36.9%
3.9%₹950.00₹865.00₹1,527.053
Feb ’24₹693.05
₹933.33
+34.7%
2.9%₹955.00₹895.00₹1,400.353
Jan ’24₹713.30
₹933.33
+30.8%
2.9%₹955.00₹895.00₹1,355.953
Dec ’23₹755.25
₹933.33
+23.6%
2.9%₹955.00₹895.00₹1,294.453
Nov ’23₹733.75
₹948.33
+29.2%
4.5%₹1,000.00₹895.00₹1,020.603

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%